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Abstract
Dysfunction in various parts of immune defence, such as
immune response, immune complex clearance, and
inflammation, has an impact on pathogenesis in systemic lupus
erythematosus (SLE). We hypothesised that combinations of
common variants of genes involved in these immune functions
are associated with susceptibility to SLE. The following variants
were analysed: HLA DR3, HLA DQ2, C4AQ0, Fcγ receptor IIa
(FcγRIIa) genotype R/R, Fcγ receptor IIIa (FcRγIIIa) genotype F/
F, mannan-binding lectin (MBL) genotype conferring a low
serum concentration of MBL (MBL-low), and interleukin-1
receptor antagonist (IL-1Ra) genotype 2/2. Polymorphisms
were analysed in 143 Caucasian patients with SLE and 200
healthy controls. HLA DR3 in SLE patients was in 90% part of
the haplotype HLA DR3-DQ2-C4AQ0, which was strongly
associated with SLE (odds ratio [OR] 2.8, 95% CI 1.7–4.5).
Analysis of combinations of gene variants revealed that the
strong association with SLE for HLA DR3-DQ2-C4AQ0
remained after combination with FcγRIIa R/R, FcγRIIIa F/F, and
MBL-low (OR>2). Furthermore, the combination of the FcγRIIa
R/R and IL-1Ra 2/2 genotypes yielded a strong correlation with
SLE (OR 11.8, 95% CI 1.5–95.4). This study demonstrates that
certain combinations of gene variants may increase
susceptibility to SLE, suggesting this approach for future
studies. It also confirms earlier findings regarding the HLA DR3-
DQ2-C4AQ0 haplotype.
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Introduction
The genetic contribution to the aetiology of systemic lupus
erythematosus (SLE) is high, as is indicated by familial
aggregation and a higher concordance rate in monozygotic
than dizygotic twins [1]. The major histocompatibility com-
plex (MHC) haplotype HLA DR3-DQ2-C4AQ0 is strongly
associated with SLE in Caucasians [2,3]. The IgG Fc
receptors appear to be important in the pathogenesis of
SLE, as recently reviewed by Salmon and Pricop [4]. With
the allelic variant of R (arginine) instead of H (histidine) on
amino acid position 131, the ability of Fcγ receptor IIa
(FcγRIIa) to bind IgG2 is diminished [5]. Similarly, an amino
acid substitution in position 158 (phenylalanine [F] instead
of valine [V]) in the Fcγ receptor IIIa (FcγRIIIa) reduces the
IgG1-, IgG3-, and IgG4-binding capacity of the receptor [6].
These variants can result in suboptimal clearance of
immune complexes from the circulation, which might con-
tribute to the pathogenesis of immune-complex-mediated
manifestations [7].
Mannan-binding lectin (MBL) is structurally similar to C1q
and has the ability to activate the complement cascade
through the lectin pathway. Point mutations are found in the
structural gene that affect the MBL serum concentration
and the stability of MBL complex formation required for effi-
cient complement activation [8]. In the promoter regions,
there are two polymorphisms that influence serum concen-
tration, with LX conferring the lowest MBL level, LY a
medium level, and HY the highest [8-11]. MBL variant alle-
ACR = American College of Rheumatology; F = phenylalanine; FcγRIIa = Fcγ receptor IIa; FcγRIIIa = Fcγ receptor IIIa; H = histidine; IL-1Ra = inter-
leukin-1 receptor antagonist; MBL = mannan-binding lectin; MBL-low/-intermediate/-high = MBL genotype conferring a low/intermediate/high serum 
concentration of MBL; MHC = major histocompatibility complex; OR = odds ratio; PCR = polymerase chain reaction; R = arginine; RERI = relative 
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les have been suggested as a minor risk factor in suscepti-
bility to SLE in several populations [8,10,12]. Interleukin-1
receptor antagonist (IL-1Ra) is a naturally occurring com-
petitive inhibitor of IL-1. The IL-1Ra gene contains a poly-
morphism in intron 2 consisting of a variable number of
copies of an 86-base-pair repeat sequence (two, three,
four, five, or six copies) [13]. An association has been found
between the IL-1Ra 2 allele and SLE [13,14]. Multiple
genes are involved in the development of SLE, and the rel-
ative importance of these genes may vary between popula-
tions and with environmental exposure. We investigated
common variant alleles involved in the immune response,
immune complex clearance, and regulation of inflammation,
with the hypothesis that combinations of polymorphic can-
didate genes could have synergistic effects on disease
susceptibility. Therefore, we have analysed polymorphisms
in the genes HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa,
MBL, and IL-1Ra and their association with the develop-
ment of SLE.
Materials and methods
Patients
The study population comprised 124 female and 14 male
Caucasian SLE patients, and 200 blood donors (100 men,
100 women) were used as controls. One hundred thirty-
eight patients fulfilled four or more criteria of the American
College of Rheumatology (ACR) classification for SLE
[15]. Five patients with a clinical SLE diagnosis were
included in the study even though they fulfilled only three
ACR classification criteria; these five patients had multisys-
temic disease with an immunologic disorder, i.e. presence
of anitnuclear antibodies and symptoms characteristic of
SLE such as arthritis, photosensitivity, serositis, nephritis,
thrombocytopenia, and leucopenia [16]. A breakdown of
the ACR criteria is shown in Table 1. There were 129 fam-
ilies with a single case of SLE and 14 families in which mul-
tiple cases were recorded. However, from each multicase
family, only the first family member with SLE diagnosis, the
index case, was included in the statistical analysis. The
mean age at diagnosis of the patients was 40 years (range
10–83) and the mean disease duration was 16 years
(range 1–42). The mean Systemic Lupus International Col-
laborating Clinics/ACR-Damage Index score was 1.9
(range 0–9) [17]. The study was approved by the local eth-
ics committee at Lund University.
Genetic analyses
DNA was extracted by the salting-out method described by
Miller and colleagues [18]. Analysis of genetic polymor-
phism was predominantly performed by polymerase chain
reaction (PCR).
HLA
HLA DR and DQ alleles were determined with PCR
(Olerup SSP™ DQ-DR SSP Combi Tray, Olerup SSP AB,
Stockholm, Sweden). However, a minority of the patients
had previously been typed with a lymphocytotoxicity test or
by restriction fragment length polymorphism as described
before [2]. C4A gene deletion was determined by PCR as
described by Grant and colleagues [19], or in a few cases
by analysis of restriction fragment length polymorphism and
determination of MHC haplotypes [2]. With the presence
of a DR3 allele together with a DQ2 and a C4AQ0 allele,
due to C4A gene deletion, the subject was considered to
have the haplotype HLA DR3-DQ2-C4AQ0, although fam-
ily studies were not uniformly performed to confirm this
assumption.
FcγRIIa gene polymorphism
The genetic polymorphism resulting in amino acid R or H in
amino acid position 131 was determined as previously
described [20].
Analysis of FcγRIIIa gene polymorphism
The analysis of the F/V polymorphism was performed
essentially as previously described [21].
MBL gene polymorphism
Variants of MBL due to mutations at codon 52 (D), 54 (B),
and 57 (C) in exon 1 of the MBL gene and promotor vari-
ants at position -550 (H/L) and -221 (X/Y) were deter-
mined by allele-specific PCR amplification, essentially as
described before [9]. The wild-type structural allele is des-
ignated A, while 0 is a description of the mutant alleles B,
C, and D. Based on previously described associations
between MBL genotype and serum concentrations, which
were confirmed in our 200 healthy controls, the MBL gen-
otypes were divided into three groups. Group 1 (MBL-low)
consisted of patients with two structural mutant alleles (0/
0) or on one haplotype a structural mutant allele together
with another haplotype containing an LX promoter and the
wild-type structural allele (ALX/0). Group 2 (MBL-interme-
diate) consisted of patients with the promoters LX confer-
ring low serum MBL on both haplotypes but with normal
structural alleles (ALX/ALX), or, alternatively, haplotypes
with one mutant and one wild-type structural allele with a
non-LX promoter together with the wild-type allele. Group
3 (MBL-high) included patients with the A/A genotype and
at least one non-LX promoter.
IL-1Ra gene polymorphism
Genetic polymorphism in the IL-1Ra gene was determined
with a PCR essentially as previously described [13,22],
although one primer was modified.
Primers: 5'-CTC AGC AAC ACT CCT AT-3'
5'-TTC CAC CAC ATG GAA C-3'Available online http://arthritis-research.com/content/6/6/R557
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The amplified fragment size depends on the number of
repeats (two repeats, designated allele 2; three, allele 4;
four, allele 1; five, allele 3; six, allele 5).
Statistics
Two group comparison tests were performed using the
Fisher exact test. Comparisons between multiple groups
were made using the χ2 multiple comparison test. Signifi-
cance was considered when P <0.05. Correction for mul-
tiple comparisons was not applied to the results, because
the study design consisted in hypothesis testing. The pres-
ence of synergistic interaction between genetic variants
was investigated by calculating relative excess risk due to
interaction (RERI) [23].
Results
A strong association between the HLA DR3-DQ2-C4AQ0
haplotype and SLE was found, although this haplotype also
was common among the controls. HLA DR2 was present in
50 of the 143 SLE patients and 72 of the 200 controls,
while DR4 frequencies were 45/143 and 72/200, respec-
tively. In the SLE group, HLA DQ2 was present in 80 of
143 cases, while DQ3 and DQ6 was recorded in 60 of
143 and 85 of 143 cases, respectively. The corresponding
numbers in the control group were for DQ2, 73/200; for
DQ3, 100/200; and for DQ6, 112/200. Other DR and DQ
variants were less common. Ninety percent of the SLE
patients with HLA DR3 displayed the haplotype DR3-DQ2-
C4AQ0, compared with 86% of the controls. The frequen-
cies of the FcγRIIa, FcγRIIIa, MBL, and IL-1Ra genotypes
are displayed in Fig. 1. The FcγRIIa R/R, FcγRIIIa F/F, IL-
1Ra 2/2, and MBL-low genotypes were not individually
associated with SLE.
Additionally, the combination of genetic variants and sus-
ceptibility to SLE was tested (Table 2). HLA DR3-DQ2-
C4AQ0 in combination with FcγRIIa R/R, FcγRIIIa F/F, or
MBL-low was still associated with SLE but did not signifi-
cantly increase the odds ratio (OR) in comparison with HLA
DR3-DQ2-C4AQ0 alone. A combination of FcγRIIa R/R
and IL-1Ra 2/2 yielded a strong association with SLE (OR
11.8), although the confidence interval was wide (1.5–
95.4). Testing of RERI did not confirm the hypothesis that
this interaction was synergistic (RERI 11.1, 95% CI -13.8
– 36.1, P = 0.38). A combined analysis of carriage rates for
the R allele and the 2 allele (i.e. the patient should have at
least one R allele and one 2 allele) was also performed, but
no significant difference was detected between the SLE
and the control group. No other combination displayed any
association with SLE.
Discussion
The increasing number of reports on polymorphic genes
involved in susceptibility to SLE prompted us to investigate
whether a combination of polymorphic candidate genes,
tentatively thought to be involved in the pathogenesis of
SLE, could further elucidate the genetic basis of the dis-
ease. In the present study we found that the combination of
the FcγRIIa R/R genotype with the IL-1Ra 2/2 genotype
was strongly associated with SLE. Although only a few of
the patients had this particular genetic background, the
results indicate that certain combinations of susceptibility
genes can be of crucial importance. Furthermore, a strong
association between the haplotype HLA DR3-DQ2-
C4AQ0 and susceptibility to SLE was seen in this study,
which is in concordance with the findings of previous stud-
ies [2,22,24,25]. The patients and controls studied were all
Table 1
Distribution of American College of Rheumatology (ACR) classification criteria in 143 patients with SLE
ACR criterion Patients
No. %
Malar rash 79 55
Discoid rash 55 38
Photosensitivity 102 71
Oral ulcers 38 27
Arthritis 118 83
Serositis 76 53
Renal disorder 38 27
Neurologic disorder 12 8
Hematologic disorder 73 51
Immunologic disorder 103 76
Antinuclear antibody 143 100Arthritis Research & Therapy    Vol 6 No 6    Jönsen et al.
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from a homogeneous Caucasian population, although a
possible bias exists in the fact that the controls used were
blood donors, which principally include only healthy individ-
uals, instead of age-matched controls from the normal pop-
ulation. The distributions of the polymorphic variants in the
controls were in agreement with data published by others
[13,26,27].
There have been ample studies on the association between
FcγRIIa and SLE [24,28-30]. However, the results are
somewhat conflicting regarding whether or not the R allele
is associated with increased susceptibility to SLE in gen-
eral or for SLE glomerulonephritis or other clinical manifes-
tations of SLE. In our study, there was no association
between either the R allele or the R/R genotype and sus-
ceptibility to SLE, with a glomerulonephritis frequency of
27%.
The MBL genotype did not seem to be involved in suscep-
tibility to SLE in our Caucasian cohort. This differs from a
finding of a recent meta-analysis in which MBL variant alle-
les were found to be associated with SLE [27]. Further-
more, in that study the conclusion was drawn that several
studies are too small to detect an increased SLE suscepti-
bility dependent on MBL risk alleles, which could also
explain the lack of association in our study.
An increased carriage rate of the 2 allele of the IL-1Ra gene
has been shown for SLE patients [13,14]. In our study, the
2/2 genotype in conjunction with the FcγRIIa R/R genotype
was associated with SLE. This IL-1Ra genotype is associ-
ated with higher IL-1 beta concentrations as well as higher
serum IL-1Ra levels [31,32]. Furthermore, immune complex
binding to Fc receptors can influence the production of IL-
1Ra [33], which provides a possibility for a pathogenetic
mechanism concordant with the genetic interaction seen in
our study. Analyses of disease phenotypes were beyond
the scope of this study and will be addressed in future stud-
ies. However, there were no apparent associations
between the various genotypes and clinical subsets of
SLE. Because of the low number of patients included in the
study, the results must be interpreted cautiously, and inde-
pendent confirmation is needed.
Conclusion
Our findings suggest that the combination of the FcγRIIa R/
R and IL-1Ra 2/2 genotypes is associated with SLE in Cau-
casian patients, whereas individually these genotypes do
not increase susceptibility to the disease. This finding illus-
trates that combinations of polymorphic genes may act in
concert in the pathogenesis of SLE, a concept that may be
instrumental in the analysis of the genetics of SLE as well
as providing hypotheses for pathways in the pathogenesis
of lupus.
Figure 1
Distribution of genetic variants studied in 143 patients with SLE and 200 healthy blood donors Distribution of genetic variants studied in 143 patients with SLE and 200 healthy blood donors. DR3 represents the haplotype DR3-DQ2-C4AQ0. 
F, phenylalanine; H, histidine; Int, intermediate; MBL, mannan-binding lectin; R, arginine; V, valine.Available online http://arthritis-research.com/content/6/6/R557
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